Akba Conversation (2024)

1. Akebia Therapeutics, Inc. (AKBA) Stock Forum & Discussion

Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and ...
Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

14 aug 2021 · The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for- ...
$AKBAMarket Price - $2.56Average Hold - $3.40Accumulate - Sub $2.45 (raised from $2.30)Price Target - $5Estimated Time Hold - 2QSupport - $2.75, $3.40Floor - $2.09Double Down Target - Sub $2Option - N/AMicro DD - In March, Akebia submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. In late May, the FDA accepted for filing the NDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for-sale securities as of June 30, 2021 were $247.0 million .

Get stock insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA). Join the AKBA discussion on Canada's largest online investor ...
Get insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA) from Canada’s largest online community of active investors.

AKBA (3-O-acetyl-11-keto-beta-boswellic acid) is één van de belangrijkste stoffen in een Boswellia extract. AKBA heeft recentelijk veel goede wetenschappelijke ...
See Also
Pytleakd.nl - Telegram: Contact... ▷ Traffic, Ranking, Analytics [May 2023] | HypeStat Obituaries in Staunton, VA | The News Leader Y For Youth 2024 | YMCA SF Run 3 Unblocked WTF Edition - Endless Running Excitement
Bestel hier de beste Boswellia Serrata supplementen. Alles op voo

17 uur geleden · Stock. Trading. -0.035. -3.13%. Quote: 1.085-3.13%. Intraday. Pre. Intraday. Post. All. Daily. Weekly. Monthly. Continue this conversation link.
The potential market implications of the FDA approving AKBA's new drug can be analyzed as follows:1. Revenue Impact: AKBA's total revenue has shown fluctuations, with the most recent quarter ending on 2023 Q3 indicating a decrease compared to the previous quarter. The FDA approval could positively impact revenue, potentially reversing the recent downward trend.2. EPS and P/E Ratio: The Basic EPS for AKBA has been negative, with slight improvements in recent quarters. The FDA approval could significantly boost EPS, potentially turning it positive. The P/E ratio, currently at -8.91, suggests negative earnings, which might change post-FDA approval.3. Market Sentiment: The market capitalization of AKBA stands at $416.67 million, reflecting investor confidence. Positive news regarding the FDA approval would likely enhance this sentiment, potentially leading to increased investment and a rise in market capitalization.In conclusion, the FDA approval of AKBA's new drug is likely to have positive market implications, impacting revenue, EPS, and market sentiment, potentially reversing recent trends and bolstering investor confidence.${富文本块}

17 apr 2015 · Find the latest Akebia Therapeutics Inc (AKBA) discussion and analysis from iHub's community of investors.
Find the latest Akebia Therapeutics Inc (AKBA) discussion and analysis from iHub's community of investors.

Bevat niet: conversation | Resultaten tonen met:conversation
See Also
User Manual — UFTP Docs
View live Akebia Therapeutics, Inc. chart to track its stock's price action. Find market predictions, AKBA financials and market news.

2 dagen geleden · Joining me for today's call, we have John Butler, Chief Executive Officer; and Dave Spellman, Chief Financial Officer. I'd like to remind ...
Akebia Therapeutics Inc (NASDAQ:AKBA) Q1-2023 earnings call transcript.

The biotech company Akebia Therapeutics Inc. trades as AKBA stock on the Nasdaq All ... Log in or sign up to join the conversation. LoginSign up. 0 Comments on ...
The biotech company Akebia Therapeutics Inc. trades as AKBA stock on the Nasdaq All Markets. Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD).

On March 21, 2013, Chinese Foreign Minister Wang Yi exchanged views on bilateral relations with his Iranian counterpart Ali Akba Salehi over the phone.
Foreign Minister Wang Yi Holds Telephone Conversation with His Iranian Counterpart Ali Akba Salehi

In their message to us, the doctor will indicate the recommendation of INFLASANUM® for you and provide your contact details. To validate the healthcare ...
MORE ABOUT THIS PRODUCT IMPORTANT: How to access this health product: To ensure safe and appropriate usage of our product, INFLASANUM® is exclusively available through healthcare professionals. To obtain this food supplement, kindly consult your healthcare provider, such as a medical doctor, naturopath, or other relevant

Trader Talk · Tech · Cybersecurity · Enterprise · Internet · Media · Mobile · Social Media · CNBC Disruptor 50 · Tech Guide · Politics · White House · Policy ...
Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.